Insider Selling: RxSight, Inc. (NASDAQ:RXST) Insider Sells 3,100 Shares of Stock

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 3,100 shares of RxSight stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $45.00, for a total value of $139,500.00. Following the completion of the transaction, the insider now owns 42,246 shares of the company’s stock, valued at approximately $1,901,070. The trade was a 6.84 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Ilya Goldshleger also recently made the following trade(s):

• On Friday, November 15th, Ilya Goldshleger sold 4,875 shares of RxSight stock. The stock was sold at an average price of $46.00, for a total value of $224,250.00.
• On Tuesday, November 12th, Ilya Goldshleger sold 1,330 shares of RxSight stock. The stock was sold at an average price of $46.13, for a total value of $61,352.90.
• On Wednesday, October 30th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The shares were sold at an average price of $51.91, for a total value of $161,180.55.
• On Friday, October 25th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.79, for a total value of $154,349.00.
• On Monday, October 28th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $50.64, for a total value of $156,984.00.
• On Tuesday, October 22nd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.68, for a total value of $154,008.00.
• On Friday, October 18th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The shares were sold at an average price of $50.09, for a total value of $155,529.45.
• On Wednesday, October 16th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.78, for a total value of $154,318.00.
• On Friday, October 11th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $50.19, for a total value of $155,589.00.
• On Monday, October 14th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $50.09, for a total value of $155,279.00.

RxSight Trading Down 0.9 %

Shares of RxSight stock traded down $0.39 during midday trading on Monday, reaching $44.66. The company had a trading volume of 482,515 shares, compared to its average volume of 490,375. The company has a market capitalization of $1.80 billion, a price-to-earnings ratio of -53.81 and a beta of 1.19. The stock has a fifty day simple moving average of $50.14 and a 200 day simple moving average of $53.15. RxSight, Inc. has a 1-year low of $27.07 and a 1-year high of $66.54.

Institutional Trading of RxSight

Hedge funds and other institutional investors have recently modified their holdings of the stock. CWM LLC increased its holdings in shares of RxSight by 727.5% in the second quarter. CWM LLC now owns 422 shares of the company’s stock valued at $25,000 after purchasing an additional 371 shares in the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of RxSight by 854.1% in the third quarter. Nisa Investment Advisors LLC now owns 582 shares of the company’s stock valued at $29,000 after purchasing an additional 521 shares in the last quarter. Quarry LP increased its holdings in shares of RxSight by 82.3% in the third quarter. Quarry LP now owns 638 shares of the company’s stock valued at $32,000 after purchasing an additional 288 shares in the last quarter. Point72 Hong Kong Ltd acquired a new stake in RxSight during the 3rd quarter worth $34,000. Finally, Quest Partners LLC acquired a new stake in RxSight during the 2nd quarter worth $41,000. Institutional investors and hedge funds own 78.78% of the company’s stock.

Analyst Upgrades and Downgrades

RXST has been the subject of a number of research analyst reports. Needham & Company LLC restated a “buy” rating and issued a $66.00 target price on shares of RxSight in a report on Friday, September 13th. Jefferies Financial Group initiated coverage on shares of RxSight in a research report on Tuesday, October 29th. They set a “buy” rating and a $72.00 target price on the stock. Oppenheimer lowered their price target on RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 6th. Stifel Nicolaus lowered their price target on RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. Finally, Wells Fargo & Company decreased their target price on RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $61.63.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.